Rutland Herald

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...

Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment

Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint. Genentech said ...
Fierce Pharma

Genentech shifts Hemlibra marketing focus to patient stories as competition approaches

Genentech has launched the “Life Doesn’t Wait” campaign to mark World Hemophilia Day, dialing up its focus on patient stories ...
The Barre-Montpelier Times Argus

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...
MM&M

Genentech taps Lorde’s ‘Royals’ director for film on rare disease caregivers

Genentech is honing in on an aspect of the patient community that is too often overlooked — the role of caregivers in managing rare diseases. In a recently-released short film, Genentech tells the ...
Fierce Biotech

AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs

Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his spare time in his backyard, sketching out designs for new ...
STAT

Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
San Diego Union-Tribune

Genentech expands in Oceanside with $450M biotech manufacturing facility and 150 jobs

Biotechnology company Genentech is expanding its local manufacturing capabilities with a $450 million investment in its Oceanside campus. Genentech was founded in 1976 and has been considered a ...

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspryng® (satralizumab) reduced the risk of a new ...
Seeking Alpha

Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

2 more drug companies to officially launch on TrumpRx

Two more drug-making giants, Abbvie and Genentech, will start selling popular medications on the White House's discounted ...
STAT

EPA fines Roche’s Genentech unit for hazardous waste violations

Following an extensive inspection, the Environmental Protection Agency fined Genentech more than $158,000 for hazardous waste violations at a facility in California, the latest instance in which a ...